THEDONEE and Precision Biosensor announced on the 4th that they signed a memorandum of understanding (MOU) to commercialize the self-potassium measurement device, Gnosis-K, for chronic kidney disease patients.

Gnosis-K is a product under development by THEDONEE, a venture company specializing in self-ion measurement devices. It is a self-diagnostic device aimed at preventing potassium shock in patients with chronic kidney disease. The device constantly monitors blood potassium ion concentration before and after symptom onset to prevent patient deterioration. It is described as a self-measurement device that can preemptively prevent dangerous conditions such as muscle paralysis and cardiac arrest.

Precision Bio provides optimized solutions for point-of-care diagnostics. Leveraging its experience in commercializing various diagnostic products, Precision Bio plans to commercialize THEDONEE's Gnosis-K. It also plans to expand into digital therapeutic services for various chronic disease patients.

Following this MOU, both companies will concretize plans for production, regulatory approval, and sales of Gnosis-K and enter into a formal contract. They also plan to discuss closely follow-up products currently under development by THEDONEE.

A company official said, "Starting with this agreement, THEDONEE's ion detection technology and Precision Bio's digital therapeutic industry for chronic diseases will create tremendous synergy, enabling us to provide excellent medical services for chronic disease patients."

https://www.hankyung.com/it/article/202211046829i